The price-to-earnings ratio for Genmab ADR (NASDAQ: GMAB) is 11.27x, which is above its average ratio. Moreover, the 36-month beta value for GMAB is 1.08. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for GMAB is 635.50M and currently, short sellers hold a 0.48% of that float. On March 26, 2025, GMAB’s average trading volume was 1.48M shares.
GMAB) stock’s latest price update
The stock price of Genmab ADR (NASDAQ: GMAB) has surged by 3.59 when compared to previous closing price of 19.06, but the company has seen a -2.49% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-25 that Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion Reduce the capital of Genmab and honor our commitments under the Restricted Stock Unit program Completion expected no later than July 10, 2025 COPENHAGEN, Denmark; March 25, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No.
GMAB’s Market Performance
Genmab ADR (GMAB) has seen a -2.49% fall in stock performance for the week, with a -14.00% decline in the past month and a -2.78% plunge in the past quarter. The volatility ratio for the week is 1.97%, and the volatility levels for the past 30 days are at 2.43% for GMAB. The simple moving average for the last 20 days is -7.19% for GMAB stock, with a simple moving average of -16.16% for the last 200 days.
Analysts’ Opinion of GMAB
Leerink Partners, on the other hand, stated in their research note that they expect to see GMAB reach a price target of $27. The rating they have provided for GMAB stocks is “Outperform” according to the report published on February 13th, 2025.
GMAB Trading at -5.66% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.35% of loss for the given period.
Volatility was left at 2.43%, however, over the last 30 days, the volatility rate increased by 1.97%, as shares sank -12.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.82% lower at present.
During the last 5 trading sessions, GMAB fell by -2.20%, which changed the moving average for the period of 200-days by -30.63% in comparison to the 20-day moving average, which settled at $21.28. In addition, Genmab ADR saw -5.39% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.95 for the gross margin
The net margin for Genmab ADR stands at 0.36. The total capital return value is set at 0.17. Equity return is now at value 23.16, with 19.54 for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 7.55. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 68.4.
Currently, EBITDA for the company is 7.39 billion with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 3.61. The receivables turnover for the company is 3.27for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.25.
Conclusion
To wrap up, the performance of Genmab ADR (GMAB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
